Long-term outcome of recombinant INF-α treatment in chronic hepatitis C in kidney transplant recipients

Special populations: treating hepatitis C in patients with decompensated cirrhosis and/or advanced renal impairment

“…Even higher SVR rates (97%) were observed in a large group of haemodialysed patients waiting for renal transplants . In post‐transplant patients, initial concerns on renal graft dysfunction and rejection associated with IFN‐based therapies were not confirmed in recent trials showing reasonable tolerance and safety …”

“…Even higher SVR rates (97%) were observed in a large group of haemodialysed patients waiting for renal transplants. 52 In post-transplant patients, initial concerns on renal graft dysfunction and rejection associated with IFN-based therapies 53,54 were not confirmed in recent trials showing reasonable tolerance and safety. 55,56 In summary, recommended HCV regimens from current guidelines in patients with advanced renal impairment are shown in Table 2. CKD 4 and 5 patients with HCV genotypes 1 and 4 should be treated with grazoprevir/elbasvir and patients with genotype 1b with the 3Dregimen.…”

Meta‐analysis: anti‐viral therapy of hepatitis C virus‐related liver disease in renal transplant patients

“…Seven studies were excluded because they contained duplicate reports of the same patients or did not fulfill the inclusion criteria; six were case reports. Twelve reports [13][14][15][16][17][18][19][20][21][22][23][24] fulfilled the inclusion criteria, 102 unique patients were enrolled in our meta-analysis. There was 100% concordance between reviewers with respect to final inclusion and exclusion of studies reviewed based on the predefined inclusion and exclusion criteria.…”

“…The literature about treatment of acute or chronic hepatitis C with IFN in the RT recipient population consists predominantly of case reports [7][8][9][10][11][12] and small clinical trials. [13][14][15][16][17][18][19][20][21][22][23][24] Data on alternative therapeutic options, such as combination therapy (IFN plus ribavirin), [22][23][24] and ribavirin [25][26][27] or amantadine 28 monotherapy are even more preliminary in nature. Although some authors have shown a beneficial effect, no review summarized the size and consistency of IFN's effect on hepatitis C in the RT population.…”

Management of Hepatitis C Infection in Renal Transplant Recipients

“…demonstrate good biochemical and virologic response and an improvement in liver histology (20,(47)(48)(49)(50)(51)(52)(53)(54)(55)(56)(57)(58)(59). However, as in the case with nonrenal patients, relapses are common after stopping treatment and long-term outcomes are not yet adequately defined (20,48,49).…”